An observational study on the outpatient care of patients with heart failure (HF) in general practice practices within FoPraNet-BW
●Completed
Retrospective observational study

An observational study on the outpatient care of patients with heart failure (HF) in general practice practices within FoPraNet-BW

Acronym: BEBOP HI

Last updated on 27 October 2026

1 Background

Chronic heart failure is one of the most complex and burdensome chronic conditions encountered in general practice, particularly among patients with the reduced left ventricular ejection fraction (HFrEF) phenotype. It is characterised by numerous comorbidities, complex disease progression and a high need for care. There is only limited knowledge of how current treatment recommendations from evidence-based guidelines are being implemented. As part of the BEBOP-HI observational study, the care of HFrEF patients was to be investigated in research practices within the FoPraNet-BW network.

2 Research question

The study had two main objectives:

  • Assessment of the feasibility of a complex recruitment process for HFrEF patients in GP research practices
  • Analysis of guideline-based drug therapy and the cost of care in relation to comorbidity and NYHA class

3 Study design & methodology

Research teams carried out an extensive screening of routine records to identify and enrol suitable patients. They retrospectively recorded data on diagnoses, comorbidities, medication and use of the healthcare system over the past 12 months in an electronic data collection form. Medication details could alternatively be exported from the Federal Medication Plan.

4 Recruitment

Between May and August 2025, 49 research practices documented a total of 337 cases (an average of 6.8 per practice). The average age was 74 years (68 % males). The average left ventricular ejection fraction was 32 %. Significant multimorbidity was evident, including concomitant arterial hypertension (82 %), coronary heart disease (68 %), atrial fibrillation (28%), diabetes mellitus (40 %) and renal insufficiency (42 %).

Prescription data for recommended drugs that improve prognosis showed that 89 % patients were treated with RAS inhibitors, 81 % with beta-blockers, 57 % were receiving SGLT2 inhibitors and 53 % were receiving mineralocorticoid receptor antagonists. Over 70 % of the patients received the guideline-recommended standard treatment comprising RAS inhibitors and beta-blockers. More than half of the symptomatic patients (NYHA ≥ II) received the recommended „quadruple therapy“ in accordance with the guidelines. Patients had an average of 24 GP visits per year and two cardiology appointments per year. The completeness of the data also allows for further analyses.

337
Participants
49
practice

5 Study results

BEBOP-HI demonstrates that even complex healthcare research studies involving extensive recruitment and structured data collection can be successfully carried out within the FoPraNet-BW. At the same time, the study provides important insights into real-world healthcare provision in a general practice setting.

Consortium leadership

  • Heidelberg University Hospital, Department of Medicine, Internal Medicine II, General Practice and Healthcare Research

Study Leaders (Principal Investigators)

  • Prof. Dr Attila Altiner
  • Prof. Dr Frank Peters-Klimm

Partner organisations

  • Tübingen University Hospital, Institute of General Practice and Interprofessional Care
  • Freiburg University Hospital, Institute of General Medicine
  • Ulm University Hospital, Institute of General Practice
  • Reutlingen University, Reutlingen Research Institute

Course profile

Status
Duration
05/2025 - 08/2025
Type of study
Retrospective observational study
Recruitment
337 participants · 49 practices
Funding reference number
01GK1904A-D
Course registration